Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom.
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2012
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions
- Acronyms H1N1 PASS UK
- Sponsors GlaxoSmithKline
- 16 Mar 2012 Actual end date changed from May 2011 to Apr 2011 as reported by ClinicalTrials.gov.
- 27 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 27 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.